AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement initiatives through the Vermont Oxford Network, including the NIC/Q Project and NIC/Q 2000, involving 34 NICUs over 2 years.
Number of subjects: 25000
Study 9917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential quarterly and annual reports based on the Network database.
Number of subjects: 25000
Study 8560329 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (acute and chronic)
Number of subjects: 0
Study 8560329 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizomania and acute schizophrenia
Number of subjects: 0
Study 8560329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 0
Study 8560329 — intervention group
Group type: COMPARATOR
Intervention: Mania
Number of subjects: 0
Study 2087535 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing factor (GRF) 1 microgram/kg
Number of subjects: 21
Study 2087535 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 21
Study 2087535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 284710 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) at doses of 0.10, 0.15, and 0.20 mg/day
Number of subjects: 0
Study 284710 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) at a dose of 0.06 mg/day
Number of subjects: 0
Study 31174547 — intervention group
Group type: EXPERIMENTAL
Intervention: Altering the order of foods ranked in ascending order of SFA content (n = 261)
Number of subjects: 1088
Study 31174547 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering swaps to a product with less SFA (n = 279)
Number of subjects: 1088
Study 31174547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of altering order and offering swaps (n = 273)
Number of subjects: 1088
Study 31174547 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 275)
Number of subjects: 1088
Study 27943410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated ultrasound rotation (2-week curriculum)
Number of subjects: 33
Study 27943410 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical school ultrasound rotation
Number of subjects: 33
Study 27943410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weeks in the emergency department as a resident
Number of subjects: 33
Study 25536535 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect induction
Number of subjects: 50
Study 25536535 — intervention group
Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 50
Study 22985270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 251
Study 22985270 — intervention group
Group type: COMPARATOR
Intervention: Long-acting β2-agonists and anticholinergics
Number of subjects: 251
Study 21411608 — intervention group
Group type: EXPERIMENTAL
Intervention: Richly fortified porridge (19 micronutrients)
Number of subjects: 743
Study 21411608 — intervention group
Group type: COMPARATOR
Intervention: Basal porridge (9 micronutrients)
Number of subjects: 743
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconciliation Errors
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Unjustified discrepancies
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconciliation Error rate
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Total medications registered
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: No discrepancies
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Justified discrepancies
Number of subjects: 603
Study 19520393 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate errors
Number of subjects: 603
Study 17382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (starting dose, 5 mg/kg/day; median duration, 27.5 days)
Number of subjects: 226
Study 17382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 226
Study 17382109 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 226
Study 15448036 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 43-9006 at 400 mg orally twice daily
Number of subjects: 41
Study 12095057 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 44
Study 12095057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10212870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens (BCL) applied to one tympanic membrane after removal of VTs
Number of subjects: 39
Study 10212870 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (control group) of the other tympanic membrane after removal of VTs
Number of subjects: 39
Study 7597016 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive health education videos displayed in waiting rooms during intervention weeks.
Number of subjects: 0
Study 7597016 — intervention group
Group type: COMPARATOR
Intervention: Control weeks (no video exposure).
Number of subjects: 0
Study 2339965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg every 8 h)
Number of subjects: 0
Study 2339965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7011164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐1% lidocaine
Number of subjects: 48
Study 7011164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine‐1% lidocaine
Number of subjects: 48
Study 7011164 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 48
Study 7011164 — intervention group
Group type: EXPERIMENTAL
Intervention: mixture of bupivacaine‐lidocaine
Number of subjects: 48
Study 7011164 — intervention group
Group type: COMPARATOR
Intervention: etidocaine
Number of subjects: 48
Study 7011164 — intervention group
Group type: EXPERIMENTAL
Intervention: mixture of etidocaine‐lidocaine
Number of subjects: 48
Study 31344073 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 530
Study 31344073 — intervention group
Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 530
Study 30387458 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash
Number of subjects: 60
Study 30387458 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 60
Study 30387458 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 60
Study 27659887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led multicomponent intervention (behavioral interviewing, text messaging, mailed progress reports, video visits)
Number of subjects: 4076
Study 27659887 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4076
Study 25010374 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg daily)
Number of subjects: 112
Study 25010374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 22834953 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 1128305
Study 21050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1,100 mg once daily for 2 weeks
Number of subjects: 100
Study 21050319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21050319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1,100 mg once daily
Number of subjects: 100
Study 17188121 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a humorous video (87-min duration)
Number of subjects: 20
Study 15764035 — intervention group
Group type: EXPERIMENTAL
Intervention: Evelle (proprietary oral supplement for skin nutrition)
Number of subjects: 62
Study 15764035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12271298 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine (ELA‐Max) cream applied after erbium:yttrium‐aluminum‐garnet (Er:YAG) laser ablation
Number of subjects: 12
Study 12271298 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 12
Study 10023275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 30
Study 10023275 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 30
Study 10023275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthesia types
Number of subjects: 30
Study 8149518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cholesterol-lowering treatment for 90 days
Number of subjects: 12
Study 2907408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 12
Study 2907408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 12
Study 2907408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly automated follow-up only (telemetry group)
Number of subjects: 210
Study 29954340 — intervention group
Group type: COMPARATOR
Intervention: Personal contact (remote+phone subgroup)
Number of subjects: 210
Study 29954340 — intervention group
Group type: COMPARATOR
Intervention: Personal contact (in-clinic visits only)
Number of subjects: 210
Study 29954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rates
Number of subjects: 210
Study 29954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HF-hospitalisation rates
Number of subjects: 210
Study 29954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetry and remote+phone groups
Number of subjects: 210
Study 29954340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICD therapy delivered
Number of subjects: 210
Study 28859020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage nonoperative treatment with additional diagnostic block if regular 2 weeks medication was not effective
Number of subjects: 66
Study 28859020 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs for 2 weeks
Number of subjects: 66
Study 26553682 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT vaccine
Number of subjects: 4004
Study 26553682 — intervention group
Group type: COMPARATOR
Intervention: PsACWY vaccine
Number of subjects: 4004
Study 24079117 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 0
Study 24079117 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricating gel
Number of subjects: 0
Study 20206179 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (within 72 hours after ES)
Number of subjects: 96
Study 20206179 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (after 6-8 weeks)
Number of subjects: 96
Study 18219532 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 390
Study 18219532 — intervention group
Group type: COMPARATOR
Intervention: St. Mark's incontinence score
Number of subjects: 390
Study 16875041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (< 30 g/day)
Number of subjects: 132
Study 16875041 — intervention group
Group type: COMPARATOR
Intervention: Caloric-Restricted Diet (< 30% of calories from fat)
Number of subjects: 132
Study 12544730 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5, 5, 7.5 or 10 mg)
Number of subjects: 37
Study 12544730 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 37
Study 10773785 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9 in bronchoalveolar lavage fluid (BALF)
Number of subjects: 24
Study 10773785 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified CA19-9
Number of subjects: 24
Study 8638533 — intervention group
Group type: EXPERIMENTAL
Intervention: FLP (5-FU, leucovorin, cisplatin)
Number of subjects: 20
Study 8638533 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAP (5-FU, leucovorin, cisplatin, Adriamycin)
Number of subjects: 20
Study 8638533 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 8102631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 52
Study 8102631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3529368 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate (Estradurin, Leo) 80 mg i.m. every fourth week + ethinyl estradiol (Etivex, Leo) 150 micrograms daily
Number of subjects: 244
Study 3529368 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (Estracyt, Leo) 280 mg twice daily
Number of subjects: 244
Study 3529368 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 244
Study 29925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Email invitation
Number of subjects: 401
Study 29925324 — intervention group
Group type: COMPARATOR
Intervention: Postal invitation
Number of subjects: 401
Study 29925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 401
Study 29925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Males 18-49 years old
Number of subjects: 401
Study 29925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents with local adverse events
Number of subjects: 401
Study 29925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents with systemic adverse events
Number of subjects: 401
Study 27433335 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week self-management training program (manual therapy, education, home exercises) with instructional workbook and video and a pedometer
Number of subjects: 0
Study 27433335 — intervention group
Group type: COMPARATOR
Intervention: Single instructional session with instructional workbook and video and pedometer
Number of subjects: 0
Study 25662413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m², four weekly infusions)
Number of subjects: 112
Study 25662413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 25662413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 112
Study 23279058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 22
Study 23279058 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 22
Study 21606869 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal-effort graded exercise test
Number of subjects: 70
Study 19115653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic wedge (group P)
Number of subjects: 60
Study 19115653 — intervention group
Group type: COMPARATOR
Intervention: Lumbar wedge (group L)
Number of subjects: 60
Study 19115653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16469211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol) applied on the gastro‐jejunal and jejuno‐jejunal anastomoses and the mesenteric openings
Number of subjects: 322
Study 16469211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue, but suture of the mesenteric openings)
Number of subjects: 322
Study 12957701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation using Integrated Psychological Treatment (IPT)
Number of subjects: 27
Study 12957701 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without cognitive impairments)
Number of subjects: 27
Study 10966535 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative T waves (NT group, n = 938, 62%)
Number of subjects: 1505
Study 10966535 — intervention group
Group type: COMPARATOR
Intervention: Positive T waves (PT group, n = 567, 38%)
Number of subjects: 1505
Study 10966535 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative T waves (NT group)
Number of subjects: 1505
Study 9192196 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (3-4 mg of elemental iron per kg body weight, 1 day per week)
Number of subjects: 173
Study 9192196 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (3-4 mg of elemental iron per kg body weight, 5 days per week)
Number of subjects: 173
Study 9192196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 8243685 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallidinogenase (600 units by mouth daily for 12 weeks)
Number of subjects: 114
Study 8243685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 3519529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60-320 mg/day)
Number of subjects: 62
Study 3519529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62
Study 3519529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60-240 mg or 320 mg/day)
Number of subjects: 62
Study 3519529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (up to 320 mg/day)
Number of subjects: 62
Study 3519529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 29428785 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements
Number of subjects: 17870
Study 29428785 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements
Number of subjects: 17870
Study 29428785 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplements only
Number of subjects: 17870
Study 29322301 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg daily for 4 weeks)
Number of subjects: 21
Study 29322301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27241898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 120
Study 27241898 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 120
Study 24105456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal care with povidone-iodine (n = 91)
Number of subjects: 179
Study 24105456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 88)
Number of subjects: 179
Study 21951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial exercise program (daily manual mouth-stretching and oral-augmentation exercises twice a day for 6 minutes for 6 months)
Number of subjects: 48
Study 21951278 — intervention group
Group type: COMPARATOR
Intervention: Usual dental care (control group)
Number of subjects: 48
Study 18832434 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12
Study 18832434 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol 0.5 mg
Number of subjects: 12
Study 18832434 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 12
Study 18832434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17593148 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills for Social and Academic Success (SASS)
Number of subjects: 36
Study 17593148 — intervention group
Group type: COMPARATOR
Intervention: Educational-supportive treatment (control)
Number of subjects: 36
Study 15957829 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection (AGI)
Number of subjects: 84
Study 15957829 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 84
Study 12397530 — intervention group
Group type: EXPERIMENTAL
Intervention: Felted foam therapy
Number of subjects: 61
Study 12397530 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61
Study 10363538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube supplementation
Number of subjects: 84
Study 10363538 — intervention group
Group type: COMPARATOR
Intervention: Bottle supplementation
Number of subjects: 84
Study 7774190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 1% in ethanol
Number of subjects: 0
Study 7774190 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study 1580032 — intervention group
Group type: EXPERIMENTAL
Intervention: 12F Foley catheter introduced after anesthesia prior to surgery
Number of subjects: 62
Study 1580032 — intervention group
Group type: COMPARATOR
Intervention: 12F Foley catheter introduced after termination of cardiopulmonary bypass period
Number of subjects: 62
Study 1580032 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheter introduced after termination of the bypass period
Number of subjects: 62
Study 1580032 — intervention group
Group type: EXPERIMENTAL
Intervention: 12F Foley catheter introduced after anesthesia (in a larger group of 39 patients)
Number of subjects: 62
Study 6233546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20
Study 6233546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20
Study 6233546 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20
Study 6233546 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20
Study 31322563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA) for adverse event monitoring
Number of subjects: 24
Study 29052766 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine supplementation (6.4 g orally/day)
Number of subjects: 144
Study 29052766 — intervention group
Group type: COMPARATOR
Intervention: placebo therapy
Number of subjects: 144
Study 26803328 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 + DTaP/IPV
Number of subjects: 749
Study 26803328 — intervention group
Group type: COMPARATOR
Intervention: saline + DTaP/IPV
Number of subjects: 749
Study 25335172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (nortriptyline and/or gabapentin plus physical therapies, up to three cervical epidural steroid injections)
Number of subjects: 169
Study 25335172 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injections (ESI)
Number of subjects: 169